Skip to main content
. 2022 Dec 10;11(24):3994. doi: 10.3390/cells11243994

Figure 6.

Figure 6

PICALM immunolabelling is increased in LOAD and FAD in correlation with the development of tau pathology. Representative immunolabelling of anti-PICALM antibody (Sigma #HPA019053) in the Cornu Ammonis regions of the hippocampus of control (A,D), LOAD (B,E) and FAD with PSEN1 mutations at R35E and E120D (C,F). In non-demented control brain, a perinuclear immunolabelling of PICALM was detected in neurons (black arrows) (A). A PICALM immunoreactivity was detected in NFTs in neuronal perikarya (blue arrows) in the affected brain areas of LOAD (B) and FAD (C). PICALM-immunoreactive microglial cells were faintly detected in control brains (arrowheads) (D), and the number and the intensity of PICALM-stained microglia were increased in LOAD (D) (arrowheads). In FAD (F) brains, the increase in PICALM immunostained microglial cells was less prominent than in LOAD. More detailed data can be found in our article [33]. Control (Ctrl), Late-onset Alzheimer’s disease (LOAD), Familial Alzheimer’s disease (FAD). Scale bar 20 µm.